FibroGen welcomes the opportunity to build alliances that complement the Company's strengths. We seek partners with research, development, and marketing capabilities and other resources that strengthen our ability to advance our product candidates.
- In 2013, FibroGen entered an licensing arrangement with AstraZeneca that provides AstraZeneca development and commercialization rights to roxadustat (FG-4592) for the treatment of anemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD). This collaboration, extends to the United States, China, and all major markets excluding those which are covered by an existing agreement between FibroGen and Astellas Pharma Inc.
- In 2006, FibroGen entered an licensing agreement with Astellas Pharma Inc. that provides Astellas development and marketing rights to roxadustat (FG-4592) and certain other FibroGen HIF prolyl hydroxylase inhibitors for the treatment of anemia in Europe, Commonwealth of Independent States (CIS), Middle East, and South Africa. The Japan rights were licensed to Yamanouchi, predecessor to Astellas, in 2004.